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Availability of suPAR in emergency
departments may improve risk
stratification: a secondary analysis of the
TRIAGE III trial
Martin Schultz1,2* , Line J. H. Rasmussen3, Thomas Kallemose3, Erik Kjøller1, Morten N. Lind4, Lisbet Ravn4,
Theis Lange5,6, Lars Køber7, Lars S. Rasmussen8, Jesper Eugen-Olsen3 and Kasper Iversen1
Abstract
Introduction: Soluble urokinase plasminogen activator receptor (suPAR) is a prognostic and nonspecific biomarker
associated with short-term mortality in emergency department (ED) patients. Therefore, the blood level of suPAR
might be usable for identification of patients at high- and low risk, shortly after arrival at the ED. Here, we
investigate the value of adding suPAR to triage and how this may impact on risk stratification regarding mortality.
Methods: The analyses were performed on the TRIAGE III cohort. Patients were triaged in four groups: Red,
Orange, Yellow, and Green. Outcome was all-cause mortality within seven days. Discriminative abilities of
triage and suPAR on mortality were assessed using the area under the curve (AUC) for receiver operating
characteristics (ROC) curves. A suPAR cut-off value was generated using the Youden’s index. Patients were
subsequently reclassified one triage level up if the suPAR level was above this cut-off and one level down if
the suPAR level was below that value.
Results: The study included 4420 patients with an available triage category and suPAR measurement. suPAR
was significantly better in predicting mortality than triage; AUC (95% confidence interval): 0.85 (0.80–0.89) vs. 0.71
(0.64–0.78), P < 0.001. Combining suPAR and triage yielded an AUC of 0.87 (0.82–0-93). The Youden’s cut-off of suPAR
was 5.9 ng/mL and reclassified triage using this value resulted in a more accurate risk stratification regarding hospital
admission and mortality.
Conclusion: Addition of suPAR to triage potentially improves prediction of short-term mortality. Measurement of
suPAR in relation to the triage process may allow a more accurate identification of ED patients at risk.
Trial registration: Clinicaltrials.gov, NCT02643459. Registered 31 December 2015. https://clinicaltrials.gov/ct2/show/
NCT02643459?cond=NCT02643459&rank=1.
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Background
Triage is the process of quickly assessing and prioritising
patients according to urgency and need for treatment
[1]. Most emergency departments (ED) use risk scoring
systems to perform triage, [1, 2] and widely used con-
ventional triage algorithms are 5-level scales relying on
measurements of vital signs and the presenting com-
plaint [1, 2]. Blood tests can also be included, [3, 4] and
risk stratification models using various biomarkers have
been shown to have high discriminative powers regard-
ing mortality in patients arriving at the EDs [5, 6].
The protein soluble urokinase plasminogen activator
receptor (suPAR) is a nonspecific biomarker that con-
tains information on presence and severity of a broad
variety of acute and chronic diseases. In addition, the
suPAR level is associated with length of stay and transfer
to the intensive care unit in patients presenting acutely
to the EDs, as well as an independent predictor of
short-term mortality [7–9]. Therefore, suPAR is a poten-
tial candidate to improve the accuracy in the triage
process, however the impact of adding suPAR has not
previously been explored.
The present study aimed to investigate if adding
suPAR to conventional triage would improve accuracy
prediction of mortality and how this may impact risk
stratification.
Methods
Setting and design
The TRIAGE III trial was a cluster-randomised interven-
tional trial investigating the effect of introducing suPAR
as a routine biomarker in the ED. In this study, we per-
formed post hoc secondary analyses investigating the ef-
fect of adding suPAR to triage in outcome prediction.
The TRIAGE III trial collected data from an unselected
population admitted to EDs at hospitals in Denmark.
The two participating hospitals have large EDs with ac-
cess to all medical specialities, general, and orthopaedic
surgery, as well as intensive care, and manage 70,000
and 85,000 annual patient visits. Both are university hospi-
tals with a catchment population of approximately
425,000 and 480,000 respectively of mostly city areas. In
interventional periods suPAR measurement was available
within 30–120min of arrival alongside routine blood tests
at acute admission (analysis of suPAR took 23min using
point-of-care equipment). In control periods suPAR was
unavailable. In the current study, we included patients’
first ED visit where both the suPAR level was determined
and a triage category was recorded. The protocol and pri-
mary results have been published [10, 11].
The EDs use the conventional triage algorithm “Danish
Emergency Process Triage” (DEPT) [12], which consist of
measurements of vital signs (blood pressure, heart
rate, level of consciousness, arterial oxygen saturation,
respiratory rate, and temperature), as well as an as-
sessment of the presenting complaint. DEPT is a local
variant of Adaptive process triage (ADAPT) [13]. The
triage algorithm categorise patients into five groups:
Red (most urgent), Orange, Yellow, Green (least ur-
gent), and Blue (minor injuries) [14]. There were few
patients triaged Blue (N = 103), and as they were
similar to the patients in the Green category, Green
and Blue categories were combined in these analyses.
Analyses
Hospital admission was defined as a stay in the ED of
more than 24 h or transfer from the ED to a stationary
ward. This definition was necessary as patients arriving
at the EDs are registered differently in the hospital re-
cords upon arrival (medical patients are registered as ad-
mitted even though some were discharged shortly after
arrival). Length of stay were calculated in all hospital ad-
missions. In the analysis, we sought to assess the ability
to improve prediction of seven-day all-cause mortality
by adding the suPAR level at arrival to the initial triage
level. First, we assessed the discriminative ability of
suPAR in predicting seven-day mortality using area
under the curve (AUC) for receiver operating character-
istics (ROC) curves.
Then, we identified a cut-off value of suPAR and used
this threshold to reclassify patients one level up in triage
category, if suPAR was above the threshold and one level
down in triage category if the suPAR value was below
the threshold.
Statistics
Continuous variables are presented with median and
interquartile range (IQR), or mean and standard devi-
ation (SD) and compared using Wilcoxon Rank-sum test
and Student’s two-sample t-test. Categorial variables are
described as number (n) and percentage (%) and com-
pared using chi-square test. The discriminative ability of
triage and suPAR to predict seven-day all-cause mortality
was analysed using AUC for ROC curves. Comparison of
AUCs was done using the Delong method [15]. Sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV) were calculated from cut-off based
on the Youden’s index in a ROC analyses using a logistic
regression [16]. Comparison of initial triage and reclassifi-
cation was done using McNemar’s test and Fischer’s exact
test. A P-value of < 0.05 was considered significant. Statis-
tics were performed in R version 3.4.1 [17, 18].
Results
Of 16,801 unique patients from the TRIAGE III popula-
tion, the triage category was available in 9082 (54.1%)
patients. In patients with triage categories 4420 (48.7%)
arrived in interventional periods and had a suPAR level
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available, thus comprising the study population (Add-
itional file 1: Figure S1). The mean age (SD) was 59.6
(20.8) years, and 2239 (50.7%) were women, and 2108
(47.7%) were admitted. The median (IQR) suPAR level
was 3.9 ng/mL (2.9–5.8). At seven days 58 (1.3%) pa-
tients had died. Baseline characteristics are displayed in
Table 1. Patients where no triage category was available
were significantly older (61.6 vs 59.7 years, P < 0.001),
more were women (55.5% vs 50.7, P < 0.001) and more
were admitted (52.2% vs. 47.7%, P < 0.001), but there
was no significant difference in all-cause mortality at
seven days (1.6% vs 1.3%, P = 0.268).
The number of patients in the triage categories were:
Red: 215 (4.9%), Orange: 1241 (28.1%), Yellow: 1243
(28.1%), and Green: 1721 (38.9%). The suPAR level in-
creased with more urgent triage categories and was
significantly higher in non-survivors compared to survi-
vors across all categories (P < 0.001).
Discriminative abilities of suPAR in predicting seven-
day mortality in all patients were significantly higher than
DEPT triage; AUC (95% CI): 0.85 (0.80–0.89) vs. 0.71
(0.64–0.78), P < 0.001. In comparison, age had a AUC of
0.78 (0.74–0.83). Combining suPAR and DEPT yielded an
AUC of 0.87 (0.82–0.93), which was not significantly
higher than suPAR alone (P = 0.16), Fig. 1. A model with
the addition of both suPAR and age to DEPT were not
significantly better than suPAR alone (P = 0.16) or suPAR
and DEPT (P = 0.10). suPAR had consistently high dis-
criminative ability for seven-day mortality in all triage
groups. (Fig. 2). The AUC for predicting hospital admis-
sion for DEPT was 0.60 (0.58–0.61) compared to the com-
bination of DEPT and suPAR: 0.86 (0.82 to 0.91), P < 0.01.
The optimal cut-off (threshold) for discriminating be-
tween survivors and non-survivors among all patients was
5.9 ng/mL (specificity: 0.77, sensitivity: 0.79, PPV: 0.05,
NPV: 1.0). In the study population 3372 (76.3%) patients
had a suPAR level below the threshold at arrival to the
ED. Sensitivity analyses showed that a cut-off ranging
from 5.5 ng/mL to 6.4 ng/mL performed equally well and
yielded qualitatively same results.
Reclassification into new triage categories was then done
according to a suPAR level above or below 5.9 ng/mL,
Table 2. The reclassified triage had significantly more pa-
tients in the most urgent triage category (Red) compared
to DEPT (9.0% vs. 4.9%, P < 0.001), significantly less pa-
tients in the Orange category (10.1% vs 28.1% P < 0.001),
Table 1 Baseline characteristics of patients at arrival at the emergency departments. Patients are grouped according to the initial
triage category
Triage category N (%) Included 4420 (100) Red 215 (4.9) Orange 1241 (28.1) Yellow1,243 (28.1) Green 1721 (38.9)
Female sex, N (%) 2239 (50.7) 92 (42.8) 643 (51.8) 602 (48.4) 902 (52.4)
Age, years, mean (SD) 59.7 (20.8) 62.3 (21.5) 63.5 (19.2) 60.5 (20.7) 55.9 (21.3)
Albumin, (g/L), median (IQR) 39 (35–43) 36 (32–40) 37 (33–40) 39 (34–43) 41 (38–44)
CRP (mg/L), median (IQR) 4 (3–32) 5 (3–33) 3 (3–23) 5 (3–35) 4 (3–41)
suPAR, ng/mL, median (IQR) 3.9 (2.9–5.8) 5.6 (3.4–7.1) 4.1 (2.9–6.0) 3.9 (2.9–5.9) 3.8 (2.8–5.4)
suPAR, patients alive at seven days, ng/mL,
median (IQR)
3.9 (2.9–5.7) 4.8 (3.2–6.5) 4.1 (2.9–6.0) 3.9 (2.9–5.8) 3.8 (2.8–5.4)
suPAR, patients dead at seven days, ng/mL,
median (IQR)
8.6 (6.0–12.8) 7.9 (5.9–9.7) 10.9 (8.1–15.0) 7.9 (6.3–11.1) 9.8 (5.3–14.7)
Cancer, N (%) 166 (3.8) 9 (4.2) 41 (3.3) 46 (3.7) 70 (4.1)
Cardiovascular disease, N (%) 956 (21.6) 79 (36.7) 419 (33.8) 239 (19,2) 219 (12.7)
Infectious disease, N (%) 830 (18.8) 50 (23.3) 207 (16.7) 228 (18.3) 345 (20.0)
Neurological disease, N (%) 341 (7.7) 27 (12.6) 117 (2.6) 99 (8.0) 98 (5.7)
General surgery, N (%) 168 (3.8) 6 (2.8) 26 (2.1) 54 (4.3) 82 (4.8)
Orthopaedic surgery, N (%) 154 (3.5) 1 (0.5) 102 (8.2) 26 (2.1) 25 (1.5)
Other, N (%) 1805 (40.8) 43 (20.0) 329 (26.5) 551 (44.3) 882 (51.2)
Herlev Hospital, N (%) 2780 (62.9) 85 (3.1) 628 (22.6) 683 (24.6) 1384 (49.8)
Bispebjerg Hospital, N (%) 1640 (37.1) 130 (8.0) 613 (37.3) 560 (34.2) 337 (20.5)
Hospital admission, N (%) 2108 (47.7) 143 (66.5) 706 (56.9) 615 (49.5) 644 (37.4)
Length of stay (days), mean (SD) 4.2 (7.1) 7.0 (11.1) 5.1 (7.9) 4.1 (6.2) 3.3 (6.2)
Surgery during admission, N (%) 444 (10.0) 15 (7.0) 164 (13.2) 112 (9.0) 153 (8.9)
Readmissions at seven days, N (%) 238 (5.4) 10 (4.7) 72 (5.8) 72 (5.8) 84 (4.9)
Mortality at seven days, N (%) 58 (1.3) 17 (7.9) 20 (1.6) 12 (1.0) 9 (0.5)
CRP C-Reactive Protein, IQR Interquartile range, SD standard deviation, suPAR Soluble urokinase plasminogen activator receptor
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same number of patients in the Yellow (P = 0.968), and fi-
nally significantly more patients classified in the least ur-
gent triage (Green) category compared to DEPT (52.3% vs.
38.9%, P < 0.001). The patients allocated to the Green
category in the reclassified triage were significantly
younger (P = 0.002) compared to DEPT, while the
patients in the remaining categories were significantly
older in the reclassified triage (Yellow: P = 0.002, Orange:
P < 0.001, Red: P < 0.001), Table 2.
After reclassification, significantly more patients were
admitted in the Red and Orange category (P < 0.001), with
a significantly higher mortality in Orange (P = 0.028) but
not in Red (P = 0.997). While the Yellow categories
remained unchanged (mortality: P = 0.676, admission:
P = 0.109), the Green category in the reclassified tri-
age had had more patients, but the same hospital ad-
mission rates (P = 0.579), and mortality (P = 0.190).
The predictive ability of the reclassified triage was sig-
nificantly better than DEPT in discriminating between
survivors and non-survivors at seven days; AUC (95% CI)
0.81 (0.76–0.87) vs. 0.71 (0.64–0.78), P < 0.001.
Discussion
This study demonstrated that addition of suPAR to the
conventional triage algorithm DEPT may improve the dis-
criminative ability regarding in seven-day mortality in a
cohort of acutely presenting medical and surgical patients.
We also found a clinically transferable cut-off of 5.9 ng/ml
allowing a more accurate risk stratification according to
mortality risk. Also, reclassification according to the
suPAR level resulted in triage categories with a better
risk stratification in relation to hospital admission and
mortality compared to DEPT.
The predictive abilities of suPAR were good in all tri-
age categories apart from Red, and in accordance with
previous reports of suPAR in emergency medicine, [7, 9]
demonstrating a robust and high discriminative ability in
relation to all-cause mortality in unselected patients ar-
riving at the ED. The predictive ability of suPAR is equal
to or better than age and other scoring systems designed
to assess patients in the ED [19]. The investigated cohort
consist of a large spectrum of patients arriving around
the clock and suffering from both medical and surgical
conditions, making this cohort suitable for testing the
impact of a non-specific biomarker in relation to overall
risk stratification.
However, if has not been determined whether use of a
prognostic biomarker for risk stratification in the ED
translates into meaningful and prognosis-changing inter-
ventions. A risk scoring system useful in emergency
medicine must be simple, easily obtainable and quickly
translatable to clinical decision making. One limitation
of using suPAR is the need for blood sampling and ana-
lysis before the level is obtained, hence reclassification
would be delayed. We used point-of-care equipment
which is currently the fastest available way to analyse
suPAR, however, the delay might make the suPAR level
redundant in patients where treatment must be initiated
immediately or within a short time frame. However, in
situations with crowding, the suPAR level could be bene-
ficial in prioritizing patients in the lower urgency classes
(Yellow and Green), who might not need immediate ac-
tion. This is the case of the majority of patients in the
EDs and identification of those in need of a higher level
of observation and faster assessment of the physician
could be beneficial. This reclassification stay could po-
tentially improve management, flow, and treatment of
patients, but this must be further assessed in randomised
interventional studies.
Limitations
The study has several limitations. The analyses are done
post hoc and do not include patients with gynaecological
or obstetric conditions, trauma patients or patients
where blood samples were not indicated. The purpose of
triage algorithms is to prioritize according to urgency,
however as no gold standard for urgency exists, we used
surrogate endpoints. We did not have data to assess other
important endpoints as time to treatment, need for anti-
biotic, iv fluids or imaging, which is also a limitation. Fur-
thermore, using mortality as a measure, also includes
patients with terminal illness in high urgency groups, who
might not need fast assessment or continuous observation,
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Fig. 1 Area under the curve for discrimination on all-cause
mortality at seven days for Danish Emergency Proces Triage
(DEPT), soluble urokinase plasminogen activator receptor (suPAR)
and the combination. DEPT vs suPAR. P < 0.001, DEPT vs
Combined: P < 0.001, suPAR vs. Combined: P = 0.016
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however, patients with a very high risk of short-term mor-
tality should ideally be assessed by a physician shortly after
arrival. There was a low mortality rate at seven days, which
introduce some uncertainties in the analyses. The cut-off
value and subsequent reclassification was done using the
same patients, and the cut-off should be validated in more
cohorts of ED patients before clinical use. Another import-
ant limitation is the fact that the proportion of patients in
the Red category almost doubled in the reclassified triage,
which might cause flow issues and tie up personnel and re-
sources. However, a subsequent reclassification of patients
in the Red and Orange categories could be used to indicate
where the most attention should be directed and ensure a
high level of observation. The Danish EDs are currently
using a local version of the National Early Warning Score
(NEWS) for this purpose after the initial triage. It has pre-
viously be shown that addition of suPAR to NEWS im-
proves risk prediction in both high- and low risk patients
[20]. In this study, we used the Youden index for calculat-
ing the suPAR cut-off to maximize both sensitivity and
specificity, as it depends on the clinical setting, whether a
rule-in or a rule-out strategy is required. However, a differ-
ent strategy could be use of a cut-off with the highest pos-
sible sensitivity for ruling out patients in risk of short-term
Table 2 Reclassification of triage categories according to the suPAR level measured at arrival
Triage category N (%) Red 396 (9.0)a Orange 445 (10.1)a Yellow 1.267 (28.7) Green 2312 (52.3)a
Female sex, N (%) 209 (52.8) 202 (45.4) 665 (52.5) 1163 (50.3)
Age, years, mean (SD) 74.8 (14.6)a 67.6 (20.0)a 62.8 (19.0)a 53.8 (20.6)a
Hospital admission, N (%) 324 (81.8)a 304 (68.3)a 665 (52.5) 815 (35.2)
Length of stay (days), mean (SD) 8.5 (11.8) 6.9 (9.5)a 4.6 (7.3) 2.8 (4.3)a
Surgery during admission, N (%) 64 (16.2)a 42 (9.4)a 135 (10.6) 203 (8.8)
Readmissions at seven days, N (%) 33 (8.3) 30 (6.7) 72 (5.9) 103 (4.5)
Mortality at seven days, N (%) 28 (7.1) 14 (3.1)a 10 (0.8) 6 (0.3)
SD: standard deviation aSignificantly different form the initial triage category
Fig. 2 Predictive ability of suPAR in discriminating all-cause mortality at seven days. Patients arriving in two emergency departments stratified according to
the triage level at arrival. Mortality in each group; Red: 17/215 (7.9%), Orange: 20/1241 (1.6%), Yellow: 12/1243 (1.0%), Green: 9/1721 (0.5%). suPAR: soluble
urokinase plasminogen activator receptor
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mortality. Additionally, using multiple cut-offs (e.g. tertiles)
might have a different impact on the reclassified triage, we
chose the single cut-off for simplicity reasons making
suPAR easy to implement in a future study. Patients with-
out an available triage category were not included, which
might represent a potential source of bias. Furthermore,
our results might not be transferable to triage algorithms
different from DEPT and the additive prognostic abilities
of suPAR should be explored in addition to other algo-
rithms as well. Finally, no randomised interventional stud-
ies to date have demonstrated that improved triage or risk
scoring systems using prognostic biomarkers leads to a bet-
ter prognosis. The TRIAGE III study aimed to investigate if
early risk stratification using suPAR would improve patient
prognosis, but found no effect on mortality, however there
was no specific intervention and the suPAR level was not
available at the time of triage.
Conclusion
Addition of the prognostic biomarker suPAR to triage
potentially improves prediction of seven-day mortality in
the emergency department. Measurement of suPAR in
relation to the triage process may allow a more accurate
identification of ED patients at high and low risk of
short-term mortality and enable a subsequent reclassifi-
cation of patients.
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